213 related articles for article (PubMed ID: 11178338)
1. Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections.
Blondeau JM
Expert Opin Investig Drugs; 2001 Feb; 10(2):213-37. PubMed ID: 11178338
[TBL] [Abstract][Full Text] [Related]
2. A review of clinical trials with fluoroquinolones with an emphasis on new agents.
Blondeau JM
Expert Opin Investig Drugs; 2000 Feb; 9(2):383-413. PubMed ID: 11060684
[TBL] [Abstract][Full Text] [Related]
3. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
4. The expanding role of fluoroquinolones.
Schaeffer AJ
Dis Mon; 2003 Feb; 49(2):129-47. PubMed ID: 12601342
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Nightingale CH
Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
Balfour JA; Lamb HM
Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
[TBL] [Abstract][Full Text] [Related]
7. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Langtry HD; Lamb HM
Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
[TBL] [Abstract][Full Text] [Related]
8. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Talan DA
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
[TBL] [Abstract][Full Text] [Related]
9. Temafloxacin: an overview.
Pankey GA
Am J Med; 1991 Dec; 91(6A):166S-172S. PubMed ID: 1662889
[TBL] [Abstract][Full Text] [Related]
10. The role of the fluoroquinolones.
Guay DR
Pharmacotherapy; 1992; 12(6 Pt 2):71S-85S. PubMed ID: 1480503
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L
Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract.
Wise R; Honeybourne D
Eur Respir J; 1999 Jul; 14(1):221-9. PubMed ID: 10489856
[TBL] [Abstract][Full Text] [Related]
13. Can fluoroquinolones be considered once-daily therapy?
Neu HC
J Clin Pharmacol; 1992 Aug; 32(8):692-7. PubMed ID: 1487557
[TBL] [Abstract][Full Text] [Related]
14. Prescribing considerations in fluoroquinolone therapy.
Gentry LO
Pharmacotherapy; 1993; 13(2 Pt 2):39S-44S. PubMed ID: 8474937
[TBL] [Abstract][Full Text] [Related]
15. The expanding role of fluoroquinolones.
Schaeffer AJ
Am J Med; 2002 Jul; 113 Suppl 1A():45S-54S. PubMed ID: 12113871
[TBL] [Abstract][Full Text] [Related]
16. Two new fluoroquinolones.
Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
[No Abstract] [Full Text] [Related]
17. Current challenges in the treatment of complicated urinary tract infections and prostatitis.
Wagenlehner FM; Naber KG
Clin Microbiol Infect; 2006 May; 12 Suppl 3():67-80. PubMed ID: 16669930
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.
Blondeau JM; Hansen GT
Expert Opin Pharmacother; 2001 Feb; 2(2):317-35. PubMed ID: 11336589
[TBL] [Abstract][Full Text] [Related]
19. [Fluoroquinolones: utilization in renal and urogenital tract infections].
Farker K; Naber KG; Fünfstück R
Med Klin (Munich); 2001 Jul; 96(7):383-90. PubMed ID: 11494913
[TBL] [Abstract][Full Text] [Related]
20. The fluoroquinolones after ciprofloxacin and ofloxacin.
Hooper DC
Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
